Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biogena Group Invest AG's earnings per share without non-recurring items for the
six
months ended in Jan. 2026 was €0.07.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2026 was €0.07.
During the past 12 months, Biogena Group Invest AG's average earnings per share (NRI) Growth Rate was -10.80% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -0.40% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -4.80% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Biogena Group Invest AG's EPS without NRI or its related term are showing as below:
WBO:BIO'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -23.3 Med: -9.5 Max: -0.4
Current: -0.4
During the past 7 years, Biogena Group Invest AG's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -0.40% per year. The lowest was -23.30% per year. And the median was -9.50% per year.
WBO:BIO's 3-Year EPS without NRI Growth Rate is ranked worse than 61.21% of 1526
companies
in the Consumer Packaged Goods industry
Industry Median: 7.3
vs WBO:BIO: -0.40
Biogena Group Invest AG (WBO:BIO) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Biogena Group Invest AG EPS without NRI Related Terms
Biogena Group Invest AG EPS without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:BIO vs KHC, GIS, HRL: EPS without NRI Comparison
For the Packaged Foods subindustry, Biogena Group Invest AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogena Group Invest AG PE Ratio without NRI vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Biogena Group Invest AG's PE Ratio without NRI falls into.
Biogena Group Invest AG EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2026 was €0.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogena Group Invest AG (WBO:BIO) has a EPS without NRI of €0.07 as of Jan. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Biogena Group Invest AG and its competitors. According to the industry distribution chart, Biogena Group Invest AG ranks #934 out of 1526 companies in the Consumer Packaged Goods industry, placing it in the top 61.2%.
Is Biogena Group Invest AG's EPS without NRI too high?
Biogena Group Invest AG's current EPS without NRI is €0.07. Based on the distribution chart, Biogena Group Invest AG ranks #934 out of 1526 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Biogena Group Invest AG has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's EPS without NRI compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biogena Group Invest AG ranks #934 out of 1526 companies for EPS without NRI. This places Biogena Group Invest AG in the lower half of its industry. The industry median EPS without NRI is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Consumer Packaged Goods company?
The median EPS without NRI among Consumer Packaged Goods companies is 7.30, based on 1,526 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Biogena Group Invest AG and its competitors. For the Consumer Packaged Goods industry, the median EPS without NRI is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogena Group Invest AG's current EPS without NRI is €0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.49, compared to a current price of €5.40 — trading 54.7% above its estimated fair value. The current EPS without NRI is €0.07. Biogena Group Invest AG's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current EPS without NRI is €0.07 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €5.40 is trading 54.7% above its estimated GF Value™ of €3.49.
GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.
Key valuation signals for WBO:BIO:
EPS without NRI: €0.07
GF Value™: €3.49 vs. price of €5.40 (54.7% above fair value)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
61GF Score
Get the complete analysis for WBO:BIO
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 
